Controversies in COX-2 inhibitor therapy. Introduction.
Abramson
S B
SB
Department of Rheumatology/Medicine, Hospital for Joint Diseases/New York University School of Medicine, 301 East 17th Street, New York, NY 10003, USA. steven.abramson@med.nyu.edu
D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000201:enzymology*; D012219:Rheumatology / Q000379:methods*
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases